Business Wire

CO-VANTAGE-DATA-CENTERS

24.4.2024 12:01:33 CEST | Business Wire | Press release

Share
Vantage Data Centers Expands EMEA Portfolio with First Dublin Campus Featuring Next-Generation Energy Solution

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into the Irish market with the development of a multi-phase data center campus (DUB1). The company will invest more than €1 billion over multiple phases to support the construction and delivery of the campus in one of the largest data center markets in Europe. The first two phases consist of 52MW of IT capacity, with the first phase expected to be operational in late 2024. Upon completion, DUB1 will mark Vantage’s 14th EMEA campus in a growing regional portfolio that spans seven countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424930079/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vantage Data Centers’ flagship Dublin campus will include 52MW of IT capacity to enable next-generation applications and digital transformation. (Graphic: Business Wire)

The company’s flagship Ireland campus will be located approximately nine miles (15 kilometers) from the Dublin City Center in Profile Park, Grange Castle, an area known for its data centers. Sited on 22 acres (nine hectares), the 405,000 square foot (38,000 square meter) campus will consist of one 32MW facility and one 20MW facility and has available land and power to add a third facility in the future. The highly efficient campus is being built in alignment with Vantage’s sustainable blueprint to deliver an industry-leading annualized Power Usage Effectiveness (PUE) of 1.2 using virtually no water for cooling.

Vantage Data Centers is committed to achieving net zero carbon emissions by 2030 and drives emission reductions through the use of renewable energy and sustainable fuel alternatives across its value chain. This aligns with Ireland’s climate action plans and with the environmental commitments of the company’s key customers.

The DUB1 campus will include an on-site 100MVA multi-fuel generation plant capable of running a combination of fuels, primarily hydrotreated vegetable oil (HVO), a renewable fuel, and gas fed by Gas Networks Ireland. Given the temporary power constraints in Dublin, this on-site generation plant will support current capacity constraints by alleviating pressure on energy demand from the grid while achieving optimal efficiency and power output. The generation plant is also capable of funneling power back to the grid, further supporting power availability in the Dublin area. In addition, Vantage plans to deploy HVO in place of conventional diesel fuel throughout its fleet of back-up generators and is working to obtain corporate power purchase agreements (CPPAs) for green energy, such as biomethane from local providers. Currently, the company is leveraging HVO for 99% of its fuel requirements during the construction phase.

“The South Dublin Chamber warmly welcomes the confidence shown in our area through the €1 billion investment by Vantage Data Centers,” said Peter Byrne, CEO, South Dublin Chamber. “Vantage Data Centers will not only be contributing to local employment and taxation but will be ensuring the safety of our data and future-proofing business for years to come with this major investment in technology.”

“With Dublin being one of the biggest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution and signifies the start of a strong partnership with local officials and the community,” said David Howson, president, EMEA at Vantage Data Centers. “Throughout this development, there will be a significant positive economic impact to the community as we employ more than 1,100 individuals during peak construction and create approximately 165 jobs to operate the campus. Vantage is committed to being a good neighbor where we build and operate data centers, and we are eager to continue working with community organizations such as Round Tower GAA Club, Newcastle Tidy Towns, St. Francis Football Club, Ballyboden St. Enda’s GAA, St. Ronan’s National School in Deansrath and others.”

“Vantage is committed to environmental responsibility and is pleased that our sustainability goals, including reducing emissions, achieving net zero carbon emissions by 2030 and maximizing energy efficiency, align closely with those of the Irish government and regulatory bodies as we continue growing Ireland’s position as a leader in the digital age for cloud computing,” said Jinél Fourie, director of public policy, EMEA at Vantage Data Centers. “As environmental technology continues to advance, including the inaugural use of a multi-fuel generation plant in Dublin, we look forward to continuing our local partnerships to explore additional solutions to enhance the local community.”

For more information on Vantage Data Centers’ campuses, please visit: https://vantage-dc.com/data-center-locations/.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit www.vantage-dc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424930079/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye